List of Therapeutic Companies in Alabama - 9

Bridge Therapeutics®, based in Birmingham, Ala., is an innovative development-stage specialty pharmaceutical company pursuing U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) approvals of a patented (U.S. Patent #8410092) drug combination, BT-205, for the treatment of chronic pain in opioid-experienced patients. The investigational drug BT-205 is a unique combination of two synergistic chronic pain drugs—the partial-agonist opioid buprenorphine and the NSAID meloxicam—delivered in a state-of-the-art sublingual formulation. The dosing and delivery method will be a commercial advantage over the current alternatives. Bridge Therapeutics'​ goal is to make the BT-205 compound and other investigational new drug candidates available to millions of patients in which addictive and potentially dangerous full-agonist opioids such as oxycodone and morphine are ineffective and/or unsatisfactory. For more information, visit www.bridgetherapeutics.com.

Concero Scientific's mission is safeguarding the Warfighter and the Homeland from biothreats by accelerating prevention, response and control solutions for infectious diseases and bioagents through research, development and integration of cutting-edge life science discoveries.

Immunowake focuses on identifying new therapies for patients who do not respond to existing treatments. Our strategy involves harnessing the body’s immune system to identify and kill cancer cells the same way pathogens are identified and targeted. Recent breakthroughs in cancer immunotherapy have demonstrated that powerful anti-tumor responses can be achieved by activating antigen specific T-cells.

Founded in 2024, Kalm Therapeutics is a pre-clinical drug development company focused on a medicated, controlled-release patch for the non-steroidal treatment of patients with mild to moderate atopic dermatitis and psoriasis. We offer a steroid-free, natural alternative to the growing number of adults and children battling eczema.

NuTech Spine was incorporated in 1994 by Founder and President, Ken Horton. Since then, NuTech has been on the cutting edge of Orthopedic, Spinal, and Sports Medicine. NuTech Spine offers quality products & services to its patients and physicians with knowledgeable staff and product literature.

Score Pharma is developing new, more potent antibody therapeutics by transforming existing clinically proven antibody therapeutics for an improved patient response. Our team is prioritizing cancer therapies such as non-Hodgkin lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), and HER2-positive breast cancer. By enhancing existing technologies with a patent-pending improvement process, we expect better therapies with a higher probability of clinical and regulatory success.

Serina Therapeutics is a privately held biotechnology company located in Huntsville, Alabama. We have developed a proprietary, clinically-validated polymer technology based on the water-soluble polymer poly(oxazoline). We call it POZ for short. Please visit our website at www.serinatherapeutics.com and review the exciting work we are doing in vaccines, Parkinson's disease, pain, oncology and cannabinoid science.

TIXiMED, Inc. is focused on developing and commercializing TXNIP inhibiting medication as a first-of-its-kind oral therapeutic for Type 1 and Type 2 diabetes. TIXiMED is the exclusive license holder for the patent (composition of matter and method of use) surrounding TIX100, a novel small molecule that normalizes pancreatic beta cell TXNIP, a detrimental protein elevated in Type 1 and Type 2 diabetes. Increased TXNIP causes pancreatic islet dysfunction and death of insulin-producing beta cells and thereby contributes to the development and progression of diabetes. Diabetes affects more than half a billion people worldwide. Those affected by Type 1 diabetes are dependent on multiple daily insulin injections or continuous insulin infusions to stay alive and manage their blood sugar. Oral anti-diabetic drugs are only approved for Type 2 diabetes, but can be associated with multiple side effects, underlining the need for novel and better oral diabetes medications for Type 1 and Type 2 diabetes. TXNIP inhibition has recently been demonstrated to be an effective and safe therapeutic approach in adults and children with recent onset Type 1 diabetes and TIX100 shows beneficial, anti-diabetic effects in 4 different mouse models. Advantages of TIX100 include oral availability, no associated hypoglycemia or weight gain, potent inhibition of detrimental TXNIP in human islets, and a favorable pharmacokinetic and safety profile. In addition, TIX100 inhibits excessive glucagon secretion and hepatic glucose production and protects against fatty liver. Thus, TIX100 holds promise for durable, weight-neutral improvement in glycemic control in Type 1 and Type 2 diabetes by targeting common underlying pathology and promoting patients' own islet cell health.

Yuva Biosciences is an anti-aging company harnessing the cutting edge of mitochondrial science to develop cosmeceuticals as well as pharmaceuticals targeted at aging-related hair loss, wrinkled skin, and reduced energy. The company has secured a multimillion dollar seed round and has also entered into licensing agreements with other companies to research and develop new aesthetics products.